NCT06139185

Brief Summary

Allergic rhinitis is one of the most common inflammatory conditions of the upper airway mucosa, especially in the pediatric population with a prevalence of approximately 25%. It is among the most common chronic inflammatory diseases globally and is caused by IgE-mediated reactions to inhaled allergens, often co-occurring with asthma and causing severe burdens and disabilities worldwide. Allergic rhinitis can in fact seriously compromise the quality of life, significantly influencing school performance, social life and the quality of sleep. It is known that the most common symptoms characterizing allergic rhinitis (itching of the nose, sneezing, rhinorrhea and nasal/sinus obstruction) are partly overlapping with those due to a condition of deviation of the nasal septum and a recent study has shown how 87 % of patients with persistent allergic rhinitis are affected by at least 1 of the 7 types of nasal septum deformity. Deviation of the nasal septum is a very frequent anatomical disorder and is present in up to 48% of children and adolescents in the general population. The deviation narrows the affected nostril canal, reducing the flow of air that passes through the nostrils, predisposing to chronic mucosal inflammation with inflammatory infiltrate and in turn increasing the risk of developing chronic rhinitis and sinusitis. There are no data in the literature that correlate nasal septum deviation with an increased risk of developing allergic rhinitis. Given these premises, the ARHINASD (Allergic Rhinitis in pediatric topics with Nasal Septum Deviation) study was designed with the primary objective of evaluating the presence of allergic rhinitis in a sample of patients with and without deviation of the nasal septum.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
69

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2023

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

November 15, 2023

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 18, 2023

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
Last Updated

September 23, 2025

Status Verified

September 1, 2025

Enrollment Period

1 year

First QC Date

November 15, 2023

Last Update Submit

September 19, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Presence of allergic rhinitis

    Complete clinical and anamnestic evaluation and allergy screening test (Skin-Prick Test).

    12 months

Secondary Outcomes (5)

  • Total IgE of nasal wash supernatant

    12 months

  • Cytokines (IL-13, IL-9, IL-33, IL-5, INFγ, β-defensin, IL-17, TNFα) of nasal wash supernatant

    12 months

  • Quality of life questionnaire

    12 months

  • Peak inspiratory nasal flow

    12 months

  • Nasal cytology

    12 months

Study Arms (2)

Patients with nasal septum deviation

Other: Data collection

Patients without nasal septum deviation

Other: Data collection

Interventions

Data collection

Patients with nasal septum deviationPatients without nasal septum deviation

Eligibility Criteria

Age6 Years - 14 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Caucasian children of both sexes aged between 6 and 14 with and without suspected deviation of the nasal septum observed at Pediatrics Section of Department of Translational Medical Sciences (University of Naples Federico II), University of Calabria (Department of Pharmacy, Health and Nutrition Sciences) and Otorhinolaryngology Unit, Penne Hospital, ASL of Pescara

You may qualify if:

  • Caucasian ethnicity
  • both sexes
  • age between 6 and 14 years
  • written informed consent.

You may not qualify if:

  • Non-Caucasian ethnicity
  • Age \<6 and \>14 years
  • Concomitant presence of:
  • chronic diseases
  • malignancies
  • immunodeficiency
  • chronic infections
  • autoimmune diseases
  • chronic inflammatory intestinal diseases
  • celiac disease
  • genetic diseases
  • metabolic diseases
  • cystic fibrosis
  • chronic pulmonary diseases
  • malformations of the cardiovascular system
  • +11 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Department of Traslational Medical Science - University of Naples Federico II

Naples, 80131, Italy

Location

University of Naples Federico II

Naples, Italy

Location

MeSH Terms

Conditions

Rhinitis, Allergic

Interventions

Data Collection

Condition Hierarchy (Ancestors)

RhinitisNose DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityOtorhinolaryngologic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor, PhD, Professor

Study Record Dates

First Submitted

November 15, 2023

First Posted

November 18, 2023

Study Start

January 1, 2023

Primary Completion

January 1, 2024

Study Completion

July 1, 2024

Last Updated

September 23, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations